We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Three trials presented at the European Society of ...

Please provide your email address to receive an email when new articles are posted on . Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after ...

The media reports that colchicine, a very old drug, has now been discovered to reduce the risk of recurrent heart disease and has a new FDA indication. Of course, the “discovery” has taken 10 years, ...

PHILADELPHIA, PA—Colchicine, an anti-inflammatory indicated for gout and pericarditis, can lower the risk of ischemic cardiovascular events in patients who’ve recently had an MI, according to the ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the risk of cardiovascular events by one third when added to standard ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I’m a 78-year-old man with a stent and a blockage in one of ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

Colchicine use was linked to a 12% reduction in the risk for total joint arthroplasty among patients with gout. Colchicine use is associated with a modest reduction in the long-term risk for total ...

Anti-inflammatory oral drug colchicine improved COVID-19 outcomes for patients with relatively mild cases, according to certain topline results from the COLCORONA trial announced in a brief press ...

Public spending on colchicine has grown exponentially over the past decade despite generics suggesting an uphill slog for patients seeking access to long-term therapy for gout or cardiac conditions.

Credit: Getty Images. Colchicine use had declined 27% by 2019 compared with before the 2010 price increase. The large colchicine price increase in 2010 led to a decrease in its use. Hospital and ...